Through effective MTA2 inhibition and disruption of downstream oncogenic signaling, AS1411-Lipm[siRNA] demonstrates a strategy that directly addresses the challenges of siRNA-based cancer therapy and the broader limitations of PDAC treatment. Here, MTA2 is linked to cancer.